Effect of artesunate.amodiaquine on mortality related to Ebola virus disease

New England Journal of Medicine

Volumn 374, Issue 1, 2016, Pages 23-32

  Gignoux, Etienne ^a,b   Azman, Andrew S ^b,d   De Smet, Martin ^e   Azuma, Philippe ^f   Massaquoi, Moses ^f   Job, Dorian ^b   Tiffany, Amanda ^a,b   Petrucci, Roberta ^b   Sterk, Esther ^b   Potet, Julien ^b   Suzuki, Motoi ^b,g   Kurth, Andreas ^h,i   Cannas, Angela ^h,k   Bocquin, Anne ^c,h   Strecker, Thomas ^h,j   Logue, Christopher ^h,l   Pottage, Thomas ^h,l   Yue, Constanze ^h,i   Cabrol, Jean Clement ^b   Serafini, Micaela ^b   Ciglenecki, Iza ^b   more..

^a EPICENTRE   (France)

^b MÉDECINS SANS FRONTIÈRES   (Switzerland)

^c INSERM   (France)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e MÉDECINS SANS FRONTIÈRES   (Belgium)

^f MINISTRY OF HEALTH AND SOCIAL WELFARE   (Liberia)

^g NAGASAKI UNIVERSITY   (Japan)

^h European Mobile Laboratory Consortium   (Germany)

ⁱ ROBERT KOCH INSTITUTE   (Germany)

^j PHILIPPS UNIVERSITY MARBURG   (Germany)

^k NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^l PUBLIC HEALTH ENGLAND   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMODIAQUINE, ARTESUNATE DRUG COMBINATION; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ADOLESCENT; ADULT; CHILD; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMAN; INFANT; LIBERIA; MALARIA; MALE; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; REGRESSION ANALYSIS; RISK; YOUNG ADULT;

ADOLESCENT; ADULT; AMODIAQUINE; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HEMORRHAGIC FEVER, EBOLA; HUMANS; INFANT; LIBERIA; MALARIA; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK; YOUNG ADULT;

EID: 84954074297     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1504605     Document Type: Article

References (22)

1. World Health Organization. Ebola situation report - 2 December 2015 (http://apps.who.int/ebola/current-situation/ebola-situation-report-2-december-2015).
2. Madrid PB, Chopra S, Manger ID, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 2013;8(4):e60579.
3. Sterk E. Filovirus haemorrhagic fever guideline. Barcelona: Médecins sans Frontières, 2008.
4. World Health Organization. Clinical management of patients with viral haemorrhagic fever. 2014 (http://www.who.int/csr/resources/publications/clinical-management-patients/en).
5. World Health Organization. Guidelines for the safe transport of infectious substances and diagnostic specimens. 1997 (http://www.who.int/csr/emc97-3.pdf).
6. World Health Organization. Case definition recommendations for Ebola or Marburg virus diseases. 2014 (http://www.who.int/csr/resources/publications/ebola/case-definition/en/).
7. Kruskal WH. A nonparametric test for the several sample problem. Ann Math Stat 1952;23:525-40.
8. Agresti A. Categorical data analysis. 3rd ed. Hoboken, NJ: Wiley, 2013.
9. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-6.
10. Bah EI, Lamah M-C, Fletcher T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 2015;372:40-7.
11. WHO Ebola Response Team. Ebola virus disease in West Africa - the first 9 months of the epidemic and forward projections. N Engl J Med 2014;371:1481-95.
12. Schieffelin JS, Shaffer JG, Goba A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014;371:2092-100.
13. Burnham K, Anderson DR. Model selection and multimodel inference. New York: Springer, 2002.
14. Falzarano D, Safronetz D, Prescott J, Marzi A, Feldmann F, Feldmann H. Lack of protection against Ebola virus from chloroquine in mice and hamsters. Emerg Infect Dis 2015;21:1065-7.
15. Taylor WR, Terlouw DJ, Olliaro PL, White NJ, Brasseur P, ter Kuile FO. Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bull World Health Org 2006;84:956-64.
16. Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986;292:721-3.
17. Yeka A, Lameyre V, Afizi K, et al. Efficacy and safety of fixed-dose artesunateamodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children. PLoS One 2014;9(12):e113311.
18. Zwang J, Dorsey G, Djimdé A, et al. Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa. Malar J 2012;11:260.
19. Novartis Pharmaceuticals. Prescribing information - Coartem, 2015 (https://www.pharma.us.novartis.com/product/pi/pdf/coartem.pdf).
20. Adjei GO, Oduro-Boatey C, Rodrigues OP, et al. Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine. Malar J 2012;11:420.
21. Rumore MM. Cardiovascular adverse effects of metoclopramide: review of literature. Int J Case Rep Images 2012;3(5):1-10. (http://www.ijcasereportsandimages.com/archive/2012/005-2012-ijcri/001-05-2012-rumore/ijcri-00105201211-rumore-full-text.php).
22. World Health Organization. Guidance on temporary malaria control measures in Ebola-affected countries, 2014 (http://apps.who.int/iris/bitstream/10665/141493/1/WHO-HTM-GMP-2014.10-eng.pdf).